Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.100 +0.030 (+2.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Allogene Q2 Cash Tops $300 Million
Via The Motley Fool
Allogene Narrows Loss in Fiscal Q2
Via The Motley Fool
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise Modestly
Allogene Therapeutics reported a Q2 2025 net loss of $0.23 per share, beating estimates, with revenue at $0. Shares rose 1% post-earnings as investors focused on cost discipline and clinical progress. 
Via Chartmill
A Look at Allogene Therapeutics's Upcoming Earnings Report
 
Via Benzinga
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
 
Via Benzinga
Allogene Therapeutics's Earnings Outlook
 
Via Benzinga
A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics
 
Via Benzinga
Analyst Ratings For Allogene Therapeutics
 
Via Benzinga
Earnings Scheduled For August 13, 2025
 
Via Benzinga
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
 
Via Benzinga
Allogene Resets Clinical Course After Patient Death In Lymphoma Study
Allogene revised its LBCL trial after a fatal adverse event linked to ALLO-647, shifting to a standard FC regimen and updating its clinical approach. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise
Baird remains bullish on Allogene, stating that the updated cema-cel data continues to support the "differentiated durability" of its allogeneic CAR-T therapy. 
Via Stocktwits
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Earnings Scheduled For March 13, 2025
 
Via Benzinga
Tuesday's session: gap up and gap down stocks
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Friday's session: top gainers and losers
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
What's going on in today's session
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Friday's session: gap up and gap down stocks
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
7 Biotech Stocks to Buy for Their Game-Changing Potential
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune... 
Via Benzinga
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
Penny stocks to buy carry a great deal of risk. However, there are a few that look interesting after due diligence. 
Via InvestorPlace
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024
ALLO stock results show that Allogene Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
 
Via Benzinga
Topics ETFs
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.